- Valbenazine Met the Primary Endpoint of Significant (p
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
Watch Neurocrine Biosciences' latest callNeurocrine Biosciences (NASDAQ:NBIX) Q2 2026 Earnings Call · Replay · Jul 30Read the transcript of Neurocrine Biosciences (NASDAQ:NBIX) Q2 2026 Earnings CallNeurocrine Biosciences' next earnings callNeurocrine Biosciences (NASDAQ:NBIX) Q3 2026 Earnings Call · Nov 2, 2026 at 4:30 PM ESTRegister
Neurocrine Biosciences, Inc. on 6ix
Story so far
- Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
- Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
Earlier from Neurocrine Biosciences
- Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
- Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
- Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
- Neurocrine Biosciences to Present at Stifel 2022 CNS Days
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
Later from Neurocrine Biosciences
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
- Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
- Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
- Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
- Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
Follow Neurocrine Biosciences into a list and get an email when it puts out news.
Follow Neurocrine Biosciences